These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 15912274)

  • 21. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans.
    Muzi M; Mankoff DA; Link JM; Shoner S; Collier AC; Sasongko L; Unadkat JD
    J Nucl Med; 2009 Aug; 50(8):1267-75. PubMed ID: 19617341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of P-gp and Bcrp as brain efflux transporters on the uptake of [
    Jung KH; Oh SJ; Kang KJ; Han SJ; Nam KR; Park JA; Lee KC; Lee YJ; Choi JY
    Synapse; 2019 Nov; 73(11):e22123. PubMed ID: 31269310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier.
    Savolainen H; Cantore M; Colabufo NA; Elsinga PH; Windhorst AD; Luurtsema G
    Mol Pharm; 2015 Jul; 12(7):2265-75. PubMed ID: 26043236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and Evaluation of New Fluorine-18 Labeled Verapamil Analogs To Investigate the Function of P-Glycoprotein in the Blood-Brain Barrier.
    Raaphorst RM; Luurtsema G; Schuit RC; Kooijman EJM; Elsinga PH; Lammertsma AA; Windhorst AD
    ACS Chem Neurosci; 2017 Sep; 8(9):1925-1936. PubMed ID: 28650628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic Modeling of (
    García-Varela L; García DV; Kakiuchi T; Ohba H; Nishiyama S; Tago T; Elsinga PH; Tsukada H; Colabufo NA; Dierckx RAJO; van Waarde A; Toyohara J; Boellaard R; Luurtsema G
    Mol Pharm; 2021 Jan; 18(1):416-428. PubMed ID: 33315404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [¹⁸F]Altanserin and small animal PET: impact of multidrug efflux transporters on ligand brain uptake and subsequent quantification of 5-HT₂A receptor densities in the rat brain.
    Kroll T; Elmenhorst D; Matusch A; Celik AA; Wedekind F; Weisshaupt A; Beer S; Bauer A
    Nucl Med Biol; 2014 Jan; 41(1):1-9. PubMed ID: 24120220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron emission tomography imaging of tissue P-glycoprotein activity during pregnancy in the non-human primate.
    Chung FS; Eyal S; Muzi M; Link JM; Mankoff DA; Kaddoumi A; O'Sullivan F; Hsiao P; Unadkat JD
    Br J Pharmacol; 2010 Jan; 159(2):394-404. PubMed ID: 20002098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantification of P-glycoprotein function at the human blood-brain barrier using [
    Mossel P; Arif WM; De Souza GS; Varela LG; van der Weijden CWJ; Boersma HH; Willemsen ATM; Boellaard R; Elsinga PH; Borra RJH; Dierckx RAJO; Lammertsma AA; Bartels AL; Luurtsema G
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3917-3927. PubMed ID: 37552369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
    Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET.
    Syvänen S; Blomquist G; Sprycha M; Höglund AU; Roman M; Eriksson O; Hammarlund-Udenaes M; Långström B; Bergström M
    Neuroimage; 2006 Sep; 32(3):1134-41. PubMed ID: 16857389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. (R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus.
    Syvänen S; Luurtsema G; Molthoff CF; Windhorst AD; Huisman MC; Lammertsma AA; Voskuyl RA; de Lange EC
    BMC Med Imaging; 2011 Jan; 11():1. PubMed ID: 21199574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Test-Retest Repeatability of [
    García-Varela L; Vállez García D; Rodríguez-Pérez M; van Waarde A; Sijbesma JWA; Schildt A; Kwizera C; Aguiar P; Sobrino T; Dierckx RAJO; Elsinga PH; Luurtsema G
    ACS Chem Neurosci; 2020 Feb; 11(4):648-658. PubMed ID: 31961646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of P-glycoprotein on pulmonary disposition of the model substrate [
    Mairinger S; Hernández-Lozano I; Filip T; Löbsch M; Stanek J; Zeitlinger M; Hacker M; Tournier N; Wanek T; Ehrhardt C; Langer O
    Eur J Pharm Sci; 2023 Apr; 183():106404. PubMed ID: 36773747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of Positron Emission Tomography Radiotracers for the GABA Transporter 1.
    Sowa AR; Brooks AF; Shao X; Henderson BD; Sherman P; Arteaga J; Stauff J; Lee AC; Koeppe RA; Scott PJH; Kilbourn MR
    ACS Chem Neurosci; 2018 Nov; 9(11):2767-2773. PubMed ID: 29763549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
    Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
    J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parametric Imaging of P-Glycoprotein Function at the Blood-Brain Barrier Using k
    Breuil L; El Biali M; Vodovar D; Marie S; Auvity S; Bauer M; Goutal S; Rodrigo S; Langer O; Tournier N
    Mol Imaging Biol; 2023 Dec; 25(6):1135-1141. PubMed ID: 37801196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [PET imaging to study the functional impact of P-glycoprotein in neuropharmacokinetics].
    Marie S; Tournier N
    Therapie; 2020; 75(6):623-632. PubMed ID: 32200996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors that limit positron emission tomography imaging of p-glycoprotein density at the blood-brain barrier.
    Kannan P; Pike VW; Halldin C; Langer O; Gottesman MM; Innis RB; Hall MD
    Mol Pharm; 2013 Jun; 10(6):2222-9. PubMed ID: 23597242
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.